Sun Pharma and ICGEB New Delhi to develop botanical drug for dengue

An agreement has been signed between ICGEB and Sun Pharmaceutical Industries for clinical development of a novel botanical drug, Cissampelos pariera (Cipa) for the treatment of dengue.

The partnership aims to develop Cipa as a safe, effective and affordable botanical drug and permits Sun Pharma access to all the intellectual properties of the drug across 17 countires. ICGEB will establish assay systems for the development of Cipa for the treatment of dengue infection.

Navin Khanna, Group Leader, Recombinant Gene Products, ICGEB New Delhi:

"India represents ~50% of the global population estimated to be at risk of dengue. Severe dengue, which is potentially fatal, correlates with very high virus load, reduction in platelet counts and haemorrhage. Antiviral therapy to reduce high virus load may be beneficial in attenuating disease severity.We have explored Indian traditional medicine, Ayurveda, to identify plants that could be a source of dengue inhibitory activity. We show that an alcoholic extract prepared from Cissampelos pareira Linn inhibited the replication of dengue viruses in living cells in culture and protected mice against dengue infection. It also showed antipyretic and anti-inflammatory effects. Importantly, this extract did not show any toxic effects in rats and did not affect platelets and red blood cells. This observation is critical as dengue fever is commonly treated with antipyretics. In a dengue-endemic resource-poor country as India, the C. pareira plant may serve as a source for the development of an inexpensive herbal formulation against dengue.

Press releases

4 May 2016
Press Release ICGEB Sun Pharma

24TwoFour: Sun Pharma signs deal with ICGEB to develop dengue drug

The Times of India: Sun Pharma, ICGEB to develop botanical drug for dengue

5 May 2016
HindustanTimes: India begins work on botanical drug to treat dengue

6 May 2016
Business Standard News: Sun Pharma partners ICGEB to develop dengue drug

The HealthSite: The pharmacological giant Sun Pharma has joined hands with ICGEB for the development of a botanical, plant-based drug for the treatment of dengue

netscribes: Sun Pharma signs agreement with ICGEB for dengue drub Cipa India would have a plant-derived drug on Dengue fever, soon



Read more about N. Khanna's work on Dengue

Go back

Cod. Fisc. 90031700322

AREA Science Park
Padriciano 99
34149 Trieste, ITALY
Tel: +39-040-37571
Fax: +39-040-226555
Address book





tl_files/FB.png tl_files/Twitter_logo_blue-1def.png tl_files/rss.png
tl_files/InstagramICGEB_gray.png tl_files/LinkedIn-InBug-2CRev2.png tl_files/YouTube.png